Down syndrome is caused by the presence of an extra copy of chromosome 21, leading to intellectual disability, characteristic physical features, and increased risk of heart defects, Alzheimer's disease, leukemia, and other conditions. It is the most common chromosomal condition, affecting about 1 in 700 births, and life expectancy has improved dramatically with modern medical care.
What's actually going on in research
Research is increasingly focused on cognitive enhancement and the prevention of early-onset Alzheimer's disease, which affects nearly all individuals with Down syndrome by their 60s due to overexpression of the amyloid precursor protein gene on chromosome 21. Trials are testing DYRK1A kinase inhibitors, GABA modulators, and antioxidants to improve cognition, as well as anti-amyloid immunotherapies to delay Alzheimer's-related decline. Adaptive clinical trial designs developed for the general Alzheimer's field are being applied specifically to this population.
Cognitive enhancement drugs
DYRK1A kinase inhibitors and GABA-A alpha 5 modulators are in trials aimed at improving learning, memory, and adaptive function by targeting molecular pathways overactive due to trisomy 21.
Alzheimer's prevention
Because virtually all adults with Down syndrome develop Alzheimer's-related brain changes, anti-amyloid monoclonal antibodies and other disease-modifying therapies are being tested in this population before or at the earliest signs of cognitive decline.
Heart defect outcomes
Surgical and catheter-based strategies for the congenital heart defects present in about half of Down syndrome births are being refined to improve long-term cardiac outcomes and quality of life.
What to know before you search
Eligibility depends on age, cognitive baseline, presence of Alzheimer's symptoms, and for cardiac trials, specific heart defect anatomy.
What types of trials are currently open
- Cognitive therapy trials — Testing drugs targeting DYRK1A, GABA, and other pathways to improve learning and memory.
- Alzheimer's prevention trials — Evaluating anti-amyloid and neuroprotective therapies to delay dementia onset in adults with Down syndrome.
- Heart defect trials — Studying surgical and catheter-based approaches for congenital heart disease in Down syndrome.
- Leukemia trials — Evaluating treatment for Down syndrome-associated acute leukemia, which has distinct biology and treatment sensitivities.
- Behavioral and developmental trials — Testing behavioral, speech, and educational interventions to maximize adaptive function.
Recently added Down Syndrome trials
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities. Participants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches. The purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available. This study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.
Effects of the Otago Exercise Program on Balance, Endurance, and Motor Coordination in Children With Down Syndrome
The study will use a quasi-experimental design conducted over ten months in pediatric physiotherapy departments of tertiary care hospitals and special education schools. It will include 30 children aged 6-14 years with mild to moderate intellectual disability, selected after eligibility screening and guardian consent. Outcomes will be assessed using BOT-2, Berg Balance Scale, MMSE-C, and Six-Minute Walk Test to measure motor skills, balance, cognition, and endurance. Ethical approval will be obtained from the Research Ethical Committee of Riphah International University, Lahore, and data will be analyzed using SPSS version 26.0.
Find Down Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.